Sickle Cell Disease - Market Insights, Epidemiology and Market Forecast - 2025

  • ID: 4401847
  • Drug Pipelines
  • 105 Pages
  • DelveInsight
1 of 4
Covers the Therapeutics Market Revenue, Treatment Practice/Algorithm and Forecasted Market Size of Sickle Cell Disease from 2017 to 2025 Segmented by Seven Major Markets

FEATURED COMPANIES

  • And others
  • Bristol-Myers Squibb
  • Novartis Pharmaceuticals
  • Pfizer Inc.
  • MORE
“Sickle Cell Disease (SCD) - Market Insights, Epidemiology and Market Forecast-2025” report provides an overview of Sickle Cell Disease, epidemiology and market trend of the Sickle Cell Disease for the United States and EU5 (Germany, Spain, Italy, France and United Kingdom). The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Sickle Cell Disease from 2017 to 2025 segmented by seven major markets. In addition, The report also includes the forecasted epidemiology of Sickle Cell Disease till 2025. The report also covers market drivers, market barriers and unmet medical need.

According to this research, the prevalent population of Sickle Cell Disease is expected to reach up to XXX cases by the end of 2025 at a CAGR of 0.85% from 2015-2025 in 6MM (excluding Japan). High prevalent cases were observed in United States as compared to EU5. The higher prevalence of Sickle Cell Disease in United States is attributed to the immigration of majority of African population in the United States.

Greater uptake by the three emerging novel drugs Endari (Emmaus Lifesciences), GBT-440 (GBT Therapeutics), and Crizanlizumab (Novartis) will primarily drive the SCD market. As the number of effective treatments for the Sickle Cell Disease increase in the market during the forecast period, the prescription medications (HU; Iron Chelators, Analegesics, Antibiotics, vaccines) market share will start to decrease. Emmaus’s Endari will be the preferred therapy for the complications associated with SCD owing to its less cost, which will give more patient access to this therapy.

United States contributes the major share of Sickle Cell Disease market as compared to EU5 countries. The therapeutic market of Sickle Cell Disease in 6MM is expected to reach USD 3.1 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits::
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Sickle Cell Disease market.
  • Organize sales and marketing efforts by identifying the best opportunities for Sickle Cell Disease in US and European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom).
  • To understand the future market competition in the Sickle Cell Disease market and Insightful review of the key market drivers and barriers.
  • The report provides historical as well as forecasted epidemiology of Sickle Cell Disease in the 6MM covering United States and EU5 (Germany, Spain, Italy, France and United Kingdom) from 2015-2025.
  • The report also covers the detailed historical and forecasted Sickle Cell Disease market covering United States and European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) from 2015-2025.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • And others
  • Bristol-Myers Squibb
  • Novartis Pharmaceuticals
  • Pfizer Inc.
  • MORE
1. Report Summary

2. Sickle Cell Disease Market Overview at a Glance
2.1. Total Market Share Distribution of Sickle Cell Disease for 6 MM in 2016
2.2. Total Market Share Distribution of Sickle Cell Disease for 6 MM in 2025

3. Disease Background and Overview: Sickle Cell Disease
3.1. Complications of Sickle Cell Disease
3.2. Classification of Sickle Cell Disease
3.3. Causes
3.4. Pathophysiology
3.5. Symptoms
3.6. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters

5. Prevalent Population of Sickle Cell Disease in 6MM

6. Epidemiology of Sickle Cell Disease

7. United States
7.1. Assumptions and Rationale
7.2. Prevalent Population of Sickle Cell Disease in United States

8. Germany
8.1. Assumptions and Rationale
8.2. Prevalent Population of Sickle Cell Disease in Germany

9. France
9.1. Assumptions and Rationale
9.2. Prevalent Population of Sickle Cell Disease in France

10. Spain
10.1. Assumptions and Rationale
10.2. Prevalent Population of Sickle Cell Disease in Spain

11. Italy
11.1. Assumptions and Rationale
11.2. Prevalent Population of Sickle Cell Disease in Italy

12. United Kingdom
12.1. Assumptions and Rationale
12.2. Prevalent Population of Sickle Cell Disease in United Kingdom

13. Japan

14. Treatment Practices
14.1. Treatment goals
14.2. Treatment Algorithm
14.2.1. Vaso-occlusive crisis: First line treatment

15. Specific pain management

16. Supportive care: Oxygen therapy

17. Hydration: Fluid replacement

18. Antibiotics

19. Transfusions
19.1. Chronic disease

20. First line treatment

21. Hydroxyurea
21.1. Second line treatments

22. Bone marrow transplantation

23. Current Unmet needs

24. Marketed Drugs for Sickle Cell Disease
24.1. Droxia: Bristol-Myers Squibb
24.1.1. Drug Description
24.1.2. Mechanism of Action
24.1.3. Regulatory Milestones
24.1.4. Advantages & Disadvantages
24.1.5. Safety and Efficacy
24.1.6. Product Profile
24.2. Endari: Emmaus Life Sciences, Inc.
24.2.1. Drug Description
24.2.2. Mechanism of Action
24.2.3. Regulatory Milestones
24.2.4. Advantages & Disadvantages
24.2.5. Safety and Efficacy
24.2.6. Product Profile

25. Emerging Drugs for Sickle Cell Disease
25.1. Key Cross Competition
25.2. Recent Safety and Efficacy Results
25.3. Crizanlizumab: Novartis Pharmaceuticals
25.3.1. Regulatory Milestones
25.3.2. Other development activities
25.3.3. Clinical Development
25.3.4. Ongoing Trials Information
25.3.5. Safety and Efficacy
25.3.6. Advantages and Disadvantages
25.3.7. Product Profile
25.4. Rivipansel: Pfizer Inc.
25.4.1. Regulatory Milestones
25.4.2. Other development activities
25.4.3. Clinical Development
25.4.4. Ongoing Trials Information
25.4.5. Safety and Efficacy
25.4.6. Advantages and Disadvantages
25.4.7. Product Profile
25.5. GBT 440: Global Blood Therapeutics, Inc.
25.5.1. Regulatory Milestones
25.5.2. Clinical Development
25.5.3. Ongoing Trials Information
25.5.4. Safety and Efficacy
25.5.5. Product Profile

26. Failed Therapies
26.1. MST-188: Mast therapeutics
26.2. Prasugrel: Eli Lilly & Company

27. Sickle Cell Disease (SCD): Market Analysis
27.1. Key Findings
27.2. Total Market Size of Sickle Cell Disease (SCD) for 6 MM in 2015-2025
27.3. Total Market Size by Therapies
27.4. Total Market Size by Country

28. United States
28.1. Market Size of Sickle Cell Disease (SCD) in United States

29. Europe

30. Germany
30.1. Market Size of Sickle Cell Disease (SCD) in Germany

31. France
31.1. Market Size of Sickle Cell Disease (SCD) in France

32. Italy
32.1. Market Size of Sickle Cell Disease (SCD) in Italy

33. Spain
33.1. Market Size of Sickle Cell Disease (SCD) in Spain

34. United Kingdom
34.1. Market Size of Sickle Cell Disease (SCD) in United Kingdom

35. Market Drivers

36. Market Barriers

37. Appendix

38. Report Methodology

39. Consulting Services

40. Disclaimer

41. About

List of Tables
Table 1: Risk of inheriting Sickle Cell Disease or Sickle Cell Trait
Table 2: Laboratory test schedule for patients with SCD
Table 3: Total Prevalent Population of Sickle Cell Disease in 6 MM (2015-2025)
Table 4: Prevalent Population of Sickle Cell Disease in United States (2015-2025)
Table 5: Prevalent Population of Sickle Cell Disease in Germany (2015-2025)
Table 6: Prevalent Population of Sickle Cell Disease in France (2015-2025)
Table 7: Prevalent Population of Sickle Cell Disease in Spain (2015-2025)
Table 8: Prevalent Population of Sickle Cell Disease in Italy (2015-2025)
Table 9: Prevalent Population of Sickle Cell Disease in United Kingdom (2015-2025)
Table 10: Pharmacological management of pain using WHO three step “Analgesic Ladder”
Table 11: Nonnarcotic Analgesics for Mild Pain in Sickle Cell Disease
Table 12: Common Opioids Used to Treat Mild to Moderate Pain in Sickle Cell Disease
Table 13: Outline of management of acute pain in opioid naïve adults
Table 14: Treatment of Complications
Table 15: Evidence based Management of Sickle Cell disease
Figure 16: Current Unmet Needs in Sickle Cell Disease
Table 17: List of Marketed Drugs for Sickle Cell Disease
Table 15: Market Size of Sickle Cell Disease (SCD) by Therapies in 6MM (USD Million) (2015-2025)
Table 14: Market Size of Sickle Cell Disease (SCD) in 6MM (USD Million) (2015-2025)
Table 16: United States Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 17: Germany Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 18: France Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 19: Italy Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 20: Spain Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Table 21: United Kingdom Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)

List of Figures
Figure 1: Survival of Children with Sickle Cell Disease-Reported by NIH
Figure 2: Complications associated with Sickle Cell Disease
Figure 2: Types of Sickle Cell Disease
Figure 4: Normal vs Sickled Red Blood Cell
Figure 4: Induction of Red-Cell Sickling by Polymerization of Deoxy-hemoglobin-S
Figure 5: Principal Mechanisms Responsible for Potassium and Water Loss in Sickle Red Cells.
Figure 6: Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
Figure 7: Total Prevalent Population of Sickle Cell Disease in 6 MM (2015-2025)
Figure 8: Prevalent Population of Sickle Cell Disease in United States (2015-2025)
Figure 9: Prevalent Population of Sickle Cell Disease in Germany (2015-2025)
Figure 10: Prevalent Population of Sickle Cell Disease in France (2015-2025)
Figure 11: Prevalent Population of Sickle Cell Disease in Spain (2015-2025)
Figure 12: Prevalent Population of Sickle Cell Disease in Italy (2015-2025)
Figure 13: Prevalent Population of Sickle Cell Disease in United Kingdom (2015-2025)
Figure 15: Treatment algorithm for SCD
Figure 16: Measure of pain intensity and location
Figure 15: United States Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 16: Germany Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 17: France Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 18: Italy Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 19: Spain Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 20: United Kingdom Market Size of Sickle Cell Disease (SCD) in USD, Million (2015-2025)
Figure 21: Market Drivers
Figure 22: Market Barriers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Global Blood Therapeutics, Inc.
  • Pfizer Inc.
  • Novartis Pharmaceuticals
  • Emmaus Life Sciences, Inc.
  • Bristol-Myers Squibb
  • And others
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll